Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Total Liabilities (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Total Liabilities for 5 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 56.04% to $6.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.9 million through Dec 2025, up 56.04% year-over-year, with the annual reading at $9.6 million for FY2025, N/A changed from the prior year.
  • Total Liabilities for Q4 2025 was $6.9 million at Neuphoria Therapeutics, down from $14.8 million in the prior quarter.
  • The five-year high for Total Liabilities was $14.8 million in Q3 2025, with the low at $4.4 million in Q4 2024.
  • Average Total Liabilities over 4 years is $7.4 million, with a median of $6.3 million recorded in 2022.
  • The sharpest move saw Total Liabilities increased 9.52% in 2023, then skyrocketed 153.7% in 2025.
  • Over 4 years, Total Liabilities stood at $6.0 million in 2022, then rose by 9.52% to $6.6 million in 2023, then crashed by 32.9% to $4.4 million in 2024, then soared by 56.04% to $6.9 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $6.9 million, $14.8 million, and $9.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.